Degludec outperforms glargine in reducing nocturnal hypoglycemia

05/21/2013 | InternalMedicineNews.com (free registration)

Type 1 diabetes patients who took high doses of insulin degludec once daily had lower rates of nocturnal hypoglycemia during the full trial and maintenance periods than those who took insulin glargine, a meta-analysis indicated. The findings were presented at the American Association of Clinical Endocrinologists annual meeting.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL